| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/06/2006 | US20060148001 Compositions and methods for treating female fertility |
| 07/06/2006 | US20060147982 32 human secreted proteins |
| 07/06/2006 | US20060147973 Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01 |
| 07/06/2006 | US20060147952 2'-O-methyl-phosphorothioate oligoribonucleotide modification; peptide nucleic acids, locked nucleic acids, and/or morpholino phosphorodiamidate oligonucleotides; splicing to skip hybridization |
| 07/06/2006 | US20060147951 "STRAP" and "STEAP" (six transmembrane epithelial antigen of the prostate) |
| 07/06/2006 | US20060147923 Nucleic acid sequences encoding novel point mutations on mglur2 and mglur3 |
| 07/06/2006 | US20060147914 evaluating ability of agents to modulate Homer protein activity, Homer protein/immunophilin-peptidylproline cis-trans isomerase interaction, and/or Homer protein/proline-type Homer ligand consensus sequence interaction to identify agents for treatment; modulation of immunosupression and neuroprotection |
| 07/06/2006 | US20060147609 Oilseed processing |
| 07/06/2006 | US20060147597 Method for making a powder containing crystalline particles of glucopyranosyl-alditols |
| 07/06/2006 | US20060147547 Bone enhancing composite |
| 07/06/2006 | US20060147542 Solid preparation containing reduced coenzyme Q10 and method for producing the same |
| 07/06/2006 | US20060147539 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery |
| 07/06/2006 | US20060147538 Nanocomposite drug delivery composition |
| 07/06/2006 | US20060147534 Methods of inhibiting or inducing bone formation |
| 07/06/2006 | US20060147525 Lipophilic drug compositions |
| 07/06/2006 | US20060147501 Collagen compositions and biomaterials |
| 07/06/2006 | US20060147496 Diagnosis of irritable bowel disorders; fibromyalgia; chronic fatique syndrome; antidepressants; tinnitus; autism; autoimmune disease; Crohn's disease; quantitative analysis of serotonine, bile acid in sample |
| 07/06/2006 | US20060147492 Medical implants and anti-scarring agents |
| 07/06/2006 | US20060147480 FDA Orange book listed patent for Follitropin alpha/beta a fertility drug; stable formulation, nonprecipitating, includes Pluronic F68 (aka Poloxamer 188), m-cresol as bacteriostat, diluent |
| 07/06/2006 | US20060147477 Immunogenic compositions |
| 07/06/2006 | US20060147474 Detection of antibodies against chamydia trachomatis PGP3 antigen in patient sera by enzyme-linked immunoassay |
| 07/06/2006 | US20060147463 HSP20 inhibits amyloidogenesis and neurotoxicity |
| 07/06/2006 | US20060147454 Human serine protease and serpin polypeptides |
| 07/06/2006 | US20060147449 Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| 07/06/2006 | US20060147448 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 07/06/2006 | US20060147447 Secreted peptides |
| 07/06/2006 | US20060147446 Humanized antibodies to human GP39, compositions, and therapeutic uses thereof |
| 07/06/2006 | US20060147443 Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages |
| 07/06/2006 | US20060147442 Biocides |
| 07/06/2006 | US20060147441 Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field |
| 07/06/2006 | US20060147440 Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure |
| 07/06/2006 | US20060147439 Protein isolated from plants (Moringa) or recombinant DNA; enzyme inhibitors; prevention and treatment of metabolic, cardiovascular, and inflammatory diseases |
| 07/06/2006 | US20060147437 Use of pigmented retinal epithelial cells for creation of an immune privilege site |
| 07/06/2006 | US20060147436 interferon type 1 receptor 1 (IFNAR1)-binding proteins, used to enhanced the exogenous therapy or treatment of cancer |
| 07/06/2006 | US20060147428 Allogeneic and xenogeneic transplantation |
| 07/06/2006 | US20060147426 Nutrient broth comprising multipotent cells for use in propagation of mesodermal, neuroectodermal, and endodermal cells; tissue engineering |
| 07/06/2006 | US20060147422 Selective induction of apoptosis to treat ocular disease |
| 07/06/2006 | US20060147421 Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 |
| 07/06/2006 | US20060147417 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
| 07/06/2006 | US20060147416 Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes |
| 07/06/2006 | US20060147395 Active enamel substance is incorporated into a polymeric matrix, which is either suitable for cellular in-growth, or is cell-occlusive, so that it is released by degradation of the polymeric matrix, by enzymatic action and/or by diffusion, therapeutic, as a prophylactic and/or as a cosmetic agent |
| 07/06/2006 | US20060147392 Agent for dissolving dental calculi and dental caries |
| 07/06/2006 | US20060147384 Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) |
| 07/06/2006 | US20060147380 Integrin targeted imaging agents |
| 07/06/2006 | US20060147376 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 07/06/2006 | US20060147373 Compositions and methods for the diagnosis and treatment of tumor |
| 07/06/2006 | US20060147372 DNA encoding MCK-10, a novel receptor tyrosine kinase |
| 07/06/2006 | DE102004060385A1 Verfahren zur Bestimmung entzündlicher Vorgänge und pharmazeutische Zusammensetzungen zur Behandlung derselben A method for determining inflammatory processes and pharmaceutical compositions for treatment of the same |
| 07/06/2006 | CA2595162A1 Pulmonary surfactant formulations |
| 07/06/2006 | CA2594561A1 Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| 07/06/2006 | CA2593035A1 Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity |
| 07/06/2006 | CA2591924A1 Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure |
| 07/06/2006 | CA2590997A1 Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease |
| 07/06/2006 | CA2590239A1 Controlled release compositions |
| 07/06/2006 | CA2589515A1 Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments |
| 07/06/2006 | CA2587793A1 Compositions for hcv treatment |
| 07/06/2006 | CA2587586A1 Compounds for flaviviridae treatment |
| 07/05/2006 | EP1677114A1 High-throughput prion assays |
| 07/05/2006 | EP1677113A1 Method for the identification of protein-protein interactions in disease related protein networks |
| 07/05/2006 | EP1676923A1 Sugar chain-cutting agent |
| 07/05/2006 | EP1676920A2 Anticoagulant fusion protein anchored to cell membrane |
| 07/05/2006 | EP1676919A1 Modified vitamin K-dependent polypeptides |
| 07/05/2006 | EP1676918A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 07/05/2006 | EP1676917A2 Novel human kinases and uses thereof |
| 07/05/2006 | EP1676912A2 Medical equipment containing a polypeptide having heparanase activity |
| 07/05/2006 | EP1676857A2 Receptor that binds trail |
| 07/05/2006 | EP1676856A1 Peptide originating in hepatitis c virus |
| 07/05/2006 | EP1676855A2 Prenyl transferase inhibitors |
| 07/05/2006 | EP1676839A2 Novel beta crystalline form of perindopril tert-butylamine salt, its preparation method and pharmaceutical compositions containing same |
| 07/05/2006 | EP1676602A1 Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis |
| 07/05/2006 | EP1676588A1 Polyarginine-modified liposome capable of transferring into nucleus |
| 07/05/2006 | EP1676551A2 Treatment of hepatitis C using hyperthermia |
| 07/05/2006 | EP1675954A1 Nucleic acids useful for triggering tumor cell lethality |
| 07/05/2006 | EP1675953A2 RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/05/2006 | EP1675949A2 RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/05/2006 | EP1675872A1 Virally-safe factor viii with a low content of higher multimers |
| 07/05/2006 | EP1675870A1 Human chemokine hcc-1 polypeptides to improve stem cell transplantation |
| 07/05/2006 | EP1675869A2 Stabilised compositions |
| 07/05/2006 | EP1675868A2 Cyclin groove inhibitors |
| 07/05/2006 | EP1675866A1 Novel triterpene derivatives, preparation thereof and use thereof |
| 07/05/2006 | EP1675614A2 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 07/05/2006 | EP1675611A2 Therapeutic applications for c-peptide |
| 07/05/2006 | EP1675610A1 Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
| 07/05/2006 | EP1675609A1 Therapeutic regimens for baff antagonists |
| 07/05/2006 | EP1675608A2 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| 07/05/2006 | EP1675607A2 Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| 07/05/2006 | EP1675606A2 Peptides and compounds that bind to thrombopoietin receptors |
| 07/05/2006 | EP1675589A2 Treatment of inflamed joints |
| 07/05/2006 | EP1675580A1 Natural menaquinone 7 compositions |
| 07/05/2006 | EP1675579A2 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 07/05/2006 | EP1675578A2 Use of effectors of glutaminyl and glutamate cyclases |
| 07/05/2006 | EP1675571A2 Nanoparticulate therapeutic biologically active agents |
| 07/05/2006 | EP1675555A2 Pharmaceutical compositions for prevention of overdose or abuse |
| 07/05/2006 | EP1675550A2 Therapeutic regimens for administering drug combinations |
| 07/05/2006 | EP1675547A2 Glucocerebroside treatment of disease |
| 07/05/2006 | EP1675480A1 Nutritional composition against side effects of chemotherapy of radiotherapy |
| 07/05/2006 | EP1497316B1 Growth hormone secretagogues |
| 07/05/2006 | EP1390049B1 Compositions for treating animal diseases and syndromes comprising transfer factor |
| 07/05/2006 | EP1389044A4 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| 07/05/2006 | EP1326644B1 Absorption enhancers |